Aurobindo Pharma Achieves Major USFDA Milestone with Diabetes Drug Approvals
In a significant development for the pharmaceutical industry, Aurobindo Pharma announced on Tuesday that it has obtained final approval from the United States Food and Drug Administration (USFDA) to manufacture and market two crucial diabetes treatments in the American market. This approval represents a substantial expansion of the company's generics portfolio in one of the world's largest pharmaceutical markets.
Details of the Approved Medications
The US drug regulator has granted approval for Dapagliflozin tablets in 5 mg and 10 mg strengths, as well as Dapagliflozin and Metformin Hydrochloride extended-release tablets in multiple dosage combinations: 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg. These medications are generic equivalents of AstraZeneca's established brands Farxiga and Xigduo XR, respectively.
Manufacturing and Launch Plans
According to the company's official statement, both products will be manufactured at Unit-IV of APL Healthcare Ltd, which operates as a wholly owned subsidiary of Aurobindo Pharma. The company has confirmed that these medications will be launched immediately following the approval, indicating a swift market entry strategy.
Market Potential and Financial Implications
The market opportunity for these approved generics is substantial. Based on IQVIA MAT data for the twelve months ending February 2026, the approved generic version of Xigduo XR addresses an estimated market worth approximately $514 million. More significantly, the approved generic version of Farxiga targets a market estimated at a remarkable $10.2 billion.
Strategic Advantages and Exclusivity Benefits
Aurobindo Pharma revealed that it was among the first abbreviated new drug application (ANDA) applicants to submit substantially complete applications with paragraph IV certifications for both products. This strategic positioning makes the company eligible for 180 days of shared generic drug exclusivity in each case, providing a competitive advantage during the initial market entry period.
Aurobindo's Growing USFDA Approval Portfolio
This latest approval adds to Aurobindo Pharma's impressive track record with the USFDA. As of March 31, 2026, the company has secured 579 ANDA approvals from the US regulatory body. This total includes 554 final approvals and 25 tentative approvals, demonstrating the company's consistent regulatory success and manufacturing capabilities.
The approval of these diabetes treatments represents a strategic expansion of Aurobindo Pharma's presence in the lucrative US generics market, particularly in the critical diabetes treatment segment where demand continues to grow steadily. This development positions the company to capture significant market share while providing more affordable treatment options for American patients managing diabetes.
